Oncolytics Biotech (ONCY) Operating Income (2011 - 2026)
Oncolytics Biotech (ONCY) posted quarterly Operating Income of -$3.0 million for Q3 2017, down 190.25% year-over-year from $3.4 million in Q3 2016, and up 30.41% quarter-over-quarter from -$4.4 million in Q2 2017.
Oncolytics Biotech (ONCY) Operating Income (2011 - 2026) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Operating Income for 7 consecutive years, with -$3.0 million the latest figure, recorded in Q3 2017.
- In Q3 2017, Operating Income fell 190.25% year-over-year to -$3.0 million; the TTM figure through Sep 2017 stood at -$15.1 million (down 333.08% YoY), while the FY2025 annual figure was -$28.7 million, down 12.46% from the prior year.
- Operating Income rose to -$3.0 million in Q3 2017 per ONCY's latest filing, from -$4.4 million in the prior quarter.
- Across five years, Operating Income topped out at $5.6 million in Q1 2014 and bottomed at -$6.7 million in Q1 2013.
- Historically, Operating Income has averaged -$128517.3 across 5 years, with a median of -$132196.5 in 2015.
- Annual changes were most pronounced in 2016 — Operating Income soared 216.78% — and 2017, when it sank 266.76%.
- Oncolytics Biotech's Operating Income stood at -$6.2 million in 2013, then climbed by 10.52% to -$5.6 million in 2014, then jumped by 35.21% to -$3.6 million in 2015, then dropped by 13.25% to -$4.1 million in 2016, then rose by 25.7% to -$3.0 million in 2017.
- Business Quant data shows ONCY's Operating Income at -$3.0 million in Q3 2017, -$4.4 million in Q2 2017, and -$3.6 million in Q1 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.98 Bn | 77.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.11 Bn | 59.92 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 55.73 Bn | 50.59 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.64 Bn | 28.33 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.32 Bn | 26.49 Bn | - | 133.12 Mn |
| 10 | Oncolytics Biotech | 98.95 Mn | 98.95 Mn | - | -9.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.38 Mn |
| Jun 30, 2025 | -4.65 Mn |
| Sep 30, 2017 | -3.04 Mn |
| Jun 30, 2017 | -4.36 Mn |
| Mar 31, 2017 | -3.57 Mn |
| Dec 31, 2016 | -4.09 Mn |
| Sep 30, 2016 | 3.36 Mn |
| Jun 30, 2016 | 2.62 Mn |
| Mar 31, 2016 | 4.09 Mn |
| Dec 31, 2015 | -3.61 Mn |
| Sep 30, 2015 | -2.88 Mn |
| Jun 30, 2015 | 3.89 Mn |
| Mar 31, 2015 | 3.61 Mn |
| Dec 31, 2014 | -5.57 Mn |
| Sep 30, 2014 | 4.68 Mn |
| Jun 30, 2014 | 4.76 Mn |
| Mar 31, 2014 | 5.57 Mn |
| Sep 30, 2013 | -6.22 Mn |
| Jun 30, 2013 | 5.13 Mn |
| Mar 31, 2013 | -6.68 Mn |